Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Gilead Sciences Inc GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.


NDAQ:GILD - Post by User

Bullboard Posts
Post by Carlos66on Jan 20, 2017 1:58pm
170 Views
Post# 25734702

$70. bottom?

$70. bottom?---2 yr. low set today, but maybe as Bret Jensen (SA) said $70. was his bottom basing target price. we are close.
---below $64. for a 3 yr. low
---below $35. for a 4 yr. low
---if this is the reaction on the day of  Trump's inauguration,  GILD is badly wounded by Trump's potential harrangs.
---if GILD closes today at the low or lower that would set the stage for much worse to come (lower lows). $70. will not hold if that is the case & $64. probably won't help. Some institutional support leaving???
---right now there are demonstrations against Trump on the streets of D.C. & they are not entirely peaceful. Noise makers, smoke bombs, police charges & maybe tear gas. And the parade hasn't even started. Not a good sign.
---tomorrow the women's parade/demonstration  against Trump begins.

carlos

Bullboard Posts